BlossomHill Therapeutics, Inc.
BLSM evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $639.8M
What it means
What to watch
Prepared research question
What matters most for BLSM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLSM
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop small molecule medicines for cancer, with a pipeline targeting EGFR-mutant NSCLC, AML/HR-MDS, and KRAS-mutant solid tumors [sec · filed 2026-08-03].
Key risk: No late-stage trials completed
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$639.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for BlossomHill Therapeutics, Inc..
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop small molecule medicines for cancer, with a pipeline targeting EGFR-mutant NSCLC, AML/HR-MDS, and KRAS-mutant solid tumors [sec · filed 2026-08-03].
- BlossomHill is a clinical-stage biopharmaceutical company focused on innovative small molecule medicines for cancer treatment [sec · filed 2026-08-03].
- The company's lead program, BH-30643, targets C797S-resistant EGFR-mutant NSCLC, with a planned registrational Phase 2 trial [sec · filed 2026-08-03].
- BH-30236 is a CLK inhibitor being developed for AML and HR-MDS [sec · filed 2026-08-03].
- BH-501284 is a pan-KRAS inhibitor in IND-enabling studies for KRAS-mutant solid tumors [sec · filed 2026-08-03].
- As of 2026-06-30, the company reported cash & equivalents of $95.4M, net income of -$23.8M, and shareholders' equity of -$174.8M [sec].
What works
- The company has a clear, focused pipeline with three distinct programs addressing high-need areas in oncology: EGFR-mutant NSCLC, AML/HR-MDS, and KRAS-mutant solid tumors [sec · filed 2026-08-03].
- BlossomHill's structure-based rational drug design approach aims to overcome limitations of existing therapies, leveraging a proven track record from its scientific founder [sec · filed 2026-08-03].
- The company has secured $95.4M in cash as of 2026-06-30, providing a runway to advance its clinical programs [sec].
What to weigh
- BlossomHill has a limited operating history (formed in June 2020) and has not completed any pivotal or late-stage clinical trials, making evaluation of its approach difficult [sec · filed 2026-08-03].
- The company has negative shareholders' equity of -$174.8M as of 2026-06-30, indicating accumulated losses exceeding assets [sec].
- All three pipeline candidates are in early stages (Phase 1/2 or IND-enabling), with no approved products or revenue from product sales [sec · filed 2026-08-03].
- The company faces significant need for additional capital, as it has no history of commercializing products and its operations are funded through offerings [sec · filed 2026-08-03].
From the filings
Quoted directly from source documents.
Company description and strategy
“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”
SEC filings · August 3, 2026
BH-30643 development plan
“Advance the clinical development ofBH-30643in C797S-resistant EGFR-mutant NSCLC.”
SEC filings · August 3, 2026
BH-501284 is a pan-KRAS inhibitor
“which is designed using a novel chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations, but sparing HRAS and NRAS.”
SEC filings · August 3, 2026
Limited operating history risk
“We have not completed any pivotal or late-stage clinical trials and we have no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of our product candidates and the prospects for our future viability.”
SEC filings · August 3, 2026
Risks & what to watch (4)›
Key risks
- No late-stage trials completed — The company has not completed any pivotal or late-stage clinical trials, making it difficult to assess product viability [sec · filed 2026-08-03].
- Negative shareholders' equity — Shareholders' equity of -$174.8M as of 2026-06-30 indicates accumulated losses exceed assets [sec].
- Dependence on additional capital — The company has no history of commercializing products and relies on offerings for funding, with limited operating history [sec · filed 2026-08-03].
- Early-stage pipeline — All candidates are in Phase 1/2 or IND-enabling studies, with no approved products or revenue [sec · filed 2026-08-03].
What to watch
- Initiation and results of the potential registrational Phase 2 trial for BH-30643 in EGFR-mutant NSCLC [sec · filed 2026-08-03].
- Progress of BH-30236 in AML and HR-MDS clinical development [sec · filed 2026-08-03].
- First-in-human clinical trial initiation for BH-501284 in KRAS-mutant solid tumors [sec · filed 2026-08-03].
- Company's ability to secure additional capital and manage cash runway given negative equity [sec].
Sources: SEC filings · SEC MD&A · Generated September 29, 2026 · How we verify sources →
Run BlossomHill Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BlossomHill Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$24M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BlossomHill Therapeutics, Inc.?
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company applying a chemistry-based approach to develop small molecule medicines for cancer, with a pipeline targeting EGFR-mutant NSCLC, AML/HR-MDS, and KRAS-mutant solid tumors [sec · filed 2026-08-03].
Who is the CEO of BlossomHill Therapeutics, Inc.?
Dr. Jingrong Jean Cui Ph.D. is the chief executive officer of BlossomHill Therapeutics, Inc. (BLSM).
Where is BlossomHill Therapeutics, Inc. headquartered?
BlossomHill Therapeutics, Inc. (BLSM) is headquartered in San Diego, CA, United States.
What therapeutic areas does BlossomHill Therapeutics, Inc. focus on?
BlossomHill Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.